Physician profile
Eric J Feit
NPI 1346701836
$20,990.35
in general payments reported to CMS, 2019-2025
20 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.62 · 2023: $666 · 2024: $662 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $2,687 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,162.50 |
| Food and Beverage | $2,687.38 |
| Education | $110.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $16,623.39 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,944.38 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $946.03 | 2023-2025 | |
| Dermavant Sciences, INC. | $337.25 | 2023-2024 | Vtama |
| Leo Pharma INC. | $264.64 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $199.52 | 2023-2025 | Otezla, Amjevita |
| Janssen Biotech, INC. | $104.97 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $95.58 | 2025 | Dupixent |
| Lilly USA, LLC | $85.00 | 2025 | Ebglyss |
| Incyte Corporation | $65.29 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $60.04 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.32 | 2022-2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $49.79 | 2024-2025 | |
| Botanix Sb INC | $42.76 | 2025 | Sofdra |
| Pfizer INC. | $29.30 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $25.00 | 2023 | Valchlor |
| Lnhc, INC | $20.99 | 2025 | Zelsuvmi |
| E.R. Squibb & Sons, L.L.C. | $19.69 | 2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.34 | 2025 | Siliq |
| Organon LLC | $11.07 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Feit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.